A Federal Reserve Stuck in Limbo

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Southbound 2x Long Nikkei ETF (07262) Drops Over 5% Intraday as Korean Index Plunge Fuels Market Risk Aversion

Risk Aversion Fades, USD/JPY Holds High-Level Consolidation

Surge in Oil Prices Stirs Rate Hike Fears; US Bond Yields Climb, Wall Street Sounds Correction Alarm

Market Risk Aversion Eases, US Dollar Index Ends Slightly Lower

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

DKSH Partners with BridgeBio to Distribute ATTR-CM Drug in Key Asia-Pacific Markets

AstraZeneca Advances Dual ATTR-CM Therapy With New Phase IIb Trial

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

AstraZeneca Targets Early Detection in China With New ATTR Heart Disease Study

BridgeBio: Advancing First-in-Class LGMD Therapy and Blockbuster ATTR Franchise Underpin Reiterated Buy and $100 Target

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Alnylam: ATTR Franchise Momentum and Strategic Investment Support Durable Growth and Buy Rating